Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Plenty of ask stacking lately..their trying to get rid ....it a POS until its not..we will get the moon shot at some stage
Dude. As part of the settlement of the other CEO when he left, a bunch of shares dropped. I have looked at the filings and the dates, its clear as day.
Paying themselves in shares…they have plenty of skin in the game and want success as bad as we do
That's why Vivos (RDGL) is trading OTCQB that he made purchases of multiple companies and had testing over years and year to come up with yttrium-90 that is now being used in pets as a therapy for cancer. Say what you will but he still owns shares in that company long term. That company would be nowhere without all that early onset work. Yes. He and management are paying themselves. That is how it works.
its Just Kons business model....
just look at his pics and smirks...he learned this games PAYS
Seems like conversions are never ending too
he said same bs with vxit but vxit---IS A COVID COMPANY LOL..jk couldnt sell one massk during a pandemic of biblical proportions
J SELLS DISCOUNTED PAR SHARES VERY WELL THOUGH
filings dont lie---jimocchio lies
I understand what they are working on. I guess at this point I’m wondering what the hold up is. Earlier this year he said Covid slowed everything down and hospitals couldn’t take us on. So what are we waiting for now? Jus the right opportunity. We have the funding right? Is this another year of meeting with hospitals or is this one imminent.
It takes just one more ever so close step of GSTC to launch this with a breakthrough trial announcement and with a high profile stud like Spivak and JK grabbing everyone's attention at Multiple Sclerosis Society meeting this past month all will be laughing and crying woulda , coulda , shoulda at this absurd discounted pps!......In it to win it and skin in the game when it happens and will watch the others chase it blue skies north! ....imho to all , tryz
It's about the potential... and I'm not going to repeat everything that they're working on because you know that...that's it
have you read the filings here? have you looked at the vxit filings...do you see years of Just Bullshit fromJK but look at what his real business model is....discount share selling scheme, salaries,huge comp, conversions
Have you heard of Radiogel. Have you ever looked in the work that it required to put something together to start a radio-isotope company together from the ground up into what it is today? Lots of shares and funding went into discovery. Thats normal. We are already at basically the end stage.
jim is no different then any #otc ceo....its all about funding their lifestyle..nothing more
trade these pos`s dont marry em
I’m surprised we are actually this high after the filing, without a hospital and clinical trials there isn’t really anything here from what I read through.
12$ in Assets and a lot of share compensation for all involved.
Thanks Aqua, makes sense now. Was confused as I knew JK had assembled a solid/experienced team...so your explanation of other management teams makes sense, thank you.
Hey Augster,
Globestar Therapeutics has been chatting with the FDA for some time in regards to the clinical trial process. Those posts are very old. We know Globestar, themselves, has a team containing individuals with specialties specific to biotech/pharma company growth.
The team,
1. James C. Katzaroff successfully negotiated with the holder of a patented treatment for Multiple Sclerosis for an exclusive perpetual license. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairman and Chief Executive Officer from 2007 through December 2016. Since December 2016 to present, Mr. Katzaroff is Senior Managing Director at KATMO, LLC.
Mr. Katzaroff is highly regarded internationally for his proven expertise in corporate organization as well as developing and implementing impactful senior-level corporate strategy. Mr. Katzaroff is passionate about fostering critical investment banking and private investor relationships as well as managing complex stakeholder relationships. Associates and clients continue to trust Mr. Katzaroff with their most critical business needs because of his passion, commitment and proven ability to be a solution provider and create win-win outcomes to the most complex issues that challenge all growth companies.
2. William “Bill” Farley to its Board of Directors. Farley’s experience in discovery and development, as well as his leadership roles at major health care organizations will bring additional resources and expertise to the AngioSoma team
3. Ms. Brooke Greenwald (not sure if she is still on the team) founded Cornerstone Communications, LTD over two decades ago. As an award-winning public relations, marketing and communications professional, Ms. Greenwald has written for hundreds of publications, created content for many of today’s most recognizable companies and their brands, managed full marketing campaigns, created and implemented major public relations and communications campaigns, and worked for some of the largest news organizations in existence today. She has focused her career on healthcare, technology, security, and communications. Greenwald is a former journalist and has worked inside most of the major news networks. Ms. Greenwald holds a master’s degree in Public Relations from the University of Maryland at College Park.
4. Steven F. Penderghast has spent the past three decades focused on clinical and product development, market development and commercialization of medical devices, capital equipment and biologics. His roles have included: clinical and regulatory affairs, product development, market development, sales management, national contracts, and corporate account management. Most recently, Steven served as Corporate Vice President, Health Systems & National Accounts with Becton Dickinson, Inc. He has marketed technologies in the areas of: Vascular and Oncology Drug Delivery, Tumor Ablation, Oncology Therapeutics, Cardiovascular Intervention, Imaging, Urology, General Surgery, and Diagnostics. Mr. Penderghast is a graduate of Pepperdine University, California.
5. Mr. David Croom is an executive management leader and entrepreneur and has broad experience with business processes. Leveraging 30+ years of experience in both large and small companies gives Croom a unique perspective with respect to the regulatory, financial, operational, and personnel-related issues faced by public companies. Mr. Croom is an effective networker and speaker who has consistently worked with everyone from Wall Street to Main Street.
6. Dr. Leonard Wisneski, MD, FACP is Clinical Professor of Medicine at George Washington University, Adjunct Faculty in the Department of Biochemistry and Molecular Biology at Georgetown University and also holds faculty positions in the Medicine and Nursing Departments at The University of Colorado. His medical practice in endocrinology and integrative medicine, spanning three decades, embodies the true meaning of integrative healthcare – an optimal combination of conventional and complementary medicine practiced with a whole-person approach delivered with reverence and humanism. Dr. Wisneski graduated from Thomas Jefferson Medical College and performed his postgraduate training in the field of Internal Medicine and Endocrinology in the George Washington University healthcare system, where he served as Chief Medical Resident in Internal Medicine.
Now, Globestar has a management team that should be able to spearhead development of the company and get Jim in the doors that he needs to try to be successful. Hospitals don't just say yes to everything, nor do they have the space at times to conduct trials, nor even answer you when you reach out.
The other management team normally comes from a specialized organization that can monitor the clinical trial process. Normally, companies would employ a Clinical Research Organization (CRO) to monitor quality control, ethical standards, and data privacy amongst other things. They are crucial to the success of FDA trials. Additionally, the company needs to put together documents, abstracts, data documents, marketing tools, and protocols that will be in place to safeguard humans during this trial so all ethical standards are being met. These documents have to be submitted to the International Review Board (IRB). The IRB is set up of scientists, non-scientists, specialists and alike that will look over all the paperwork to see if it meets ethical and regulated standards. Usually, the head of these documents is the Principal Investigator (PI) that will be taking on the FDA clinical trial at their hospital. I assume the PI is the clinical researcher who has agreed and signed a Clinical Research Agreement (CRA) with Globestar to conduct the trials. It's his/her/they name on the line as they are the one's taking control of the trial process from there on out.
So when he means another management team, this is what I mean. It's a separate team that monitors and conducts the clinical trial. Some of these steps can be ready to be sent but have to wait until a specific clinical researcher at a hospital signs off.
I'm slowly piecing together this entire process as well.
What do you make of this Aqua, and others: https://twitter.com/cowboy_starfish/status/1561857548696932352?s=21&t=iKXnnZybKVlI0k1uveoJAg
Building out management team to commence trials, search out debt financing, etc. guess I’m a bit confused exactly where they’re at. Know they’re trying to line up a hospital, but what exactly do they mean when they say assemble management team to commence trials? At times I fee they’re right there, and other times not sure exactly. Also wonder on that other tweet, know you saw regarding merger candidates…if any validity to that. They’re bout due for another update, as they’ve been consistent with that over past several months…as long as they have something to say.
I understand…
I guess i was of the mindset slowly but surely before
Now I’m more like well hopefully they get something
Guess my confidence here is starting to waiver a bit
They are talking to hospitals. Getting into a hospital isn't the fastest thing in the world.
I feel like they’ve been initiating discussions with the FDA for like two years now.
Guess this is nothing until it’s not.
Still Holding and Hoping for something good soon.
Imo nothing in the filing makes me want to buy more here.
Seems like we are in the same position after every filing, guess maybe inching closer to the end goal, i didn’t think it would happen fast but again idk if I’m seeing progress
HOW THE SEC LETS THESE CEOS RAPE THE PUBLIC IS MIND BOGGLING...THESE SO CALLED COMPANIES DONT GENERATE 1 DOLLAR IN REVENUES......THEY ARE ALL SHARE SELLING ENRICHMENT SCHEMES FOR CEO/INSIDERS AND FRIENDS
another atm here for jim like vxit...wow
same business model..sell discounted shares and consultants and comps are insane for a .0035 pipe dream
https://ih.advfn.com/stock-market/USOTC/globestar-therapeutics-pk-GSTC/stock-news/88891196/quarterly-report-10-q
In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company fir a period of five years unless mutually terminated sooner. Concurrently, the Consultant entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares will be completed by June 30, 2022.
The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.
The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years.
The Consultant also received 39,000,000 warrants with an exercise price of $0.009 per share, and an exercise period of 5 years. The Company estimated the fair value of the warrants to be $322,266 which was recognized as general and administrative expense during the nine months ended June 30, 2022, using the following assumptions: 1) volatility of 254.4%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years. The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with the Consultant receiving an equal amount of warrants as those instruments that are issued. The exercise price of these additional warrants will be 110% of the price per equity equivalent, and they will vest 50% immediately and the remainder over two years.
Note 8. Subsequent Events
Subsequent to June 30, 2022, the holders of the Series G Preferred Stock converted a total of 25,000 shares and dividends of $1,000 into 9,629,630 shares of common stock.
On July 21, 2022, the holder of the Series F Preferred Stock converted 128,993 shares of Series F into 12,899,30 shares of common stock.
During the nine months ended June 30, 2022, the Company sold an aggregate of 327,250 shares of Series G Preferred Stock for net cash proceeds of $275,000. The Company recorded a debt discount of $52,250 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $327,250. The Company amortized $44,046 of discount related to Series G Preferred Stock for the nine months ended June 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $12,953 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,619 and $1,281 as of June 30, 2022 and September 30, 2021, respectively. During the six months ended June 30, 2022, the holder of the Series G converted 25,000 shares of Series G into 5,416,667 shares of common stock, and the Company recognized a loss of $10,821.
Fwiw, much that is obvious gets ignored here.
Interesting you are all of a sudden working the OTC program on this stock as it really hasn't been doing anything as of yet. One thing you have to know is everyone bought for what is possible. So thank you for point out the obvious.
10-Q out: No sales, no assets, $1million owed.
Snooze Fest
Nothing new.
Probably won't be for a very very long time... if ever.
ZZZzzzzzzzzz...
What do you mean stacked?
Wonder if Jim knows the power of telling a story and being social with updates. Could be a cult stock
Gotta be in it to win it :)
lotto tikket..they all are
Wait until there 100s mil in volume. This thing will fly. Looks Thin on the way up.
It's coming...I just keep adding
https://fb.watch/e-CVfMV1s6/
GSTC = soon to hit JACKPOT
Maybe I’m wrong, but it seems like the only thing missing here is someone who wants to run trials…..
i see you cant stand that lying Kon artist either. Kool.
Just Kon scamaroff
see vxit. same pos ceo
No, the OS is close to 700,000,000, restricted is and other DTCC shares brings this into the 500,000,000s. Obviously the restricted will become unrestricted at some point. But in terms of what is currently tradeable in the market it is different.
This is the OTC and companies big and small require funds to pay for heaps of things. It is the nature of the beast. If this is a real biotech company, they will do their best to do what they can, otherwise, this could just die into oblivion like the other bloated beasts.
It is what it is. As a biotech, this is a highly sought after pps.
Well to be clear, 700,000,000 & climbing monthly
Correct. The float is still low to mid 500,000,000. Which is tiny. At current pps ranges, the warrants/notes/salaries will keep on increasing the OS without a doubt. As the pps moves higher, the number of shares dumping into the OS will significantly decrease. Time will tell but once the show gets rolling, I wouldnt worry about the OS anymore. My guess is it will top off max at 1 bill OS. But that is just my educated guess.
OS has steadily been rising these last 5 months ...
OS increased by like 9mil i beleive
Honestly the timeline for every aspect of clinical trials is important, but none of them matter unless we get a hospital. It's great to be ready to run, just need a hospital.
The float is still in the 500s.. potential for a FDA and biotech… this is insane
All the chatter here is making me think people see a bargain. Maybe I’ll add a few more to this lotto ticket.
im sure they are jk par holders.noone can trust that ahole anymore
It’s a patent for a combination of drugs they are trying to bring to market.. they don’t sell things. Either it’s nothing or billions
Followers
|
273
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
26809
|
Created
|
03/01/12
|
Type
|
Free
|
Moderators m$teamworkotc Pokerpro05 Aquahoya |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |